These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2074513)

  • 1. A protocol for bladder cancer screening and medical surveillance among high-risk groups: the Drake Health Registry experience.
    Marsh GM; Callahan C; Pavlock D; Leviton LC; Talbott EO; Hemstreet G
    J Occup Med; 1990 Sep; 32(9):881-6. PubMed ID: 2074513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Drake Health Registry Study: findings from fifteen years of continuous bladder cancer screening.
    Marsh GM; Cassidy LD
    Am J Ind Med; 2003 Feb; 43(2):142-8. PubMed ID: 12541268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drake Chemical Workers' Health Registry Study: I. Notification and medical surveillance of a group of workers at high risk of developing bladder cancer.
    Marsh GM; Leviton LC; Talbott EO; Callahan C; Pavlock D; Hemstreet G; Logue JN; Fox J; Schulte P
    Am J Ind Med; 1991; 19(3):291-301. PubMed ID: 2008919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation issues in the Drake Chemical Workers Notification and Health Registry Study.
    Leviton LC; Chen HT; Marsh GM; Talbott EO
    Am J Ind Med; 1993 Jan; 23(1):197-204. PubMed ID: 8422051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drake Chemical Workers' Health Registry: coping with community tension over toxic exposures.
    Leviton LC; Marsh GM; Talbott E; Pavlock D; Callahan C
    Am J Public Health; 1991 Jun; 81(6):689-93. PubMed ID: 2029036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bladder cancer screening program for a petrochemical cohort with potential exposure to beta-napthylamine.
    Felknor SA; Delclos GL; Lerner SP; Burau KD; Wood SM; Lusk CM; Jalayer AD
    J Occup Environ Med; 2003 Mar; 45(3):289-94. PubMed ID: 12661186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bladder cancer screening at the Dupont Chambers Works: a new initiative.
    Mason TJ; Vogler WJ
    J Occup Med; 1990 Sep; 32(9):874-7. PubMed ID: 2074511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in screening protocols for the detection of early bladder cancer.
    Geller AC; Brooks DR; Barber CE; Koh HK; Lew RA; Wax S; Prout MN
    J Occup Med; 1990 Sep; 32(9):929-35. PubMed ID: 2074522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The identification and control of occupational bladder cancer.
    Parkes HG
    IARC Sci Publ (1971); 1979; (25):47-58. PubMed ID: 378817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for bladder cancer at the Du Pont Chambers Works: initial findings.
    Mason TJ; Prorok PC; Neeld WE; Vogler WJ
    J Occup Med; 1986 Oct; 28(10):1011-6. PubMed ID: 3772535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder cancer screening study initiated by Fox Chase.
    Oncology (Williston Park); 1990 Jan; 4(1):16. PubMed ID: 2144178
    [No Abstract]   [Full Text] [Related]  

  • 12. Quantitative fluorescence image analysis in bladder cancer screening.
    Hemstreet GP; Hurst RE; Bass RA; Rao JY
    J Occup Med; 1990 Sep; 32(9):822-8. PubMed ID: 2074505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic importance of specific immunoreactivity in occupational bladder cancer.
    Kumar S; Taylor G; Wilson P; Hurst W
    Br Med J; 1980 Feb; 280(6213):512-3. PubMed ID: 7370564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for bladder cancer in high-risk groups: delineation of the problem.
    Schulte PA
    J Occup Med; 1990 Sep; 32(9):789-92. PubMed ID: 2074499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Retrospective analysis of carcinogenic hazards of beta naphthylamine and benzidine production as a stage of an epidemiological study of tumors in workers engaged in aniline dye industry].
    Bul'bulian MA; Gol'dfarb AN
    Gig Tr Prof Zabol; 1991; (7):39-41. PubMed ID: 1916415
    [No Abstract]   [Full Text] [Related]  

  • 16. Lymphocyte reactivity of workers exposed to carcinogenic and non-carcinogenic chemicals.
    Kumar S; Taylor G; Hurst W; Wilson P; Costello CB
    Br J Ind Med; 1981 May; 38(2):167-9. PubMed ID: 7236542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periodic urine cytology surveillance of bladder tumor incidence in dyestuff workers.
    Yamaguchi N; Tazaki H; Okubo T; Toyama T
    Am J Ind Med; 1982; 3(2):139-48. PubMed ID: 7138633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Notification and risk assessment for bladder cancer of a cohort exposed to aromatic amines. III. Mortality among workers exposed to aromatic amines in the last beta-naphthylamine manufacturing facility in the United States.
    Stern FB; Murthy LI; Beaumont JJ; Schulte PA; Halperin WE
    J Occup Med; 1985 Jul; 27(7):495-500. PubMed ID: 4032086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Occupational bladder tumors among persons subjected to carcinogenic amino compound exposure: the epidemiology and prevention].
    Bul'bulian MA
    Urol Nefrol (Mosk); 1991; (4):12-8. PubMed ID: 1949409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved nuclear fluorescence screening technique.
    Hemstreet GP; West SS; Cook MS
    J Occup Med; 1986 Oct; 28(10):1004-10. PubMed ID: 3772534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.